The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

European shares fell on Tuesday as heavyweight Novo Nordisk slumped, while U.S. President Donald Trump's vocal attacks on ...

Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...

The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...

"With these costs trending so nicely downward, just what I predicted they would do, there can almost be no inflation, but ...